Abstract
Rho proteins belong to the Ras superfamily of small GTPases and function as binary switches that shuttle between active and inactive states based on the nature of bound guanine nucleotide. Three sets of regulatory proteins, namely, guanine dissociation inhibitors, guanine exchange factors, and GTPase activating proteins (GAPs) control the balance between active and inactive Rho proteins. There are more than 70 RhoGAPs encoded in the human genome. The RhoGAP family is distinguished by the presence of the RhoGAP domain. However, the majority of RhoGAPs contain multiple additional domains. There are as many as eight domains in some of these proteins. The modular structure of GAPs is important for their interaction with other proteins. A significant number of RhoGAPs have been shown to be present in altered abundance in a variety of human cancers or cell lines. The ability of RhoGAPs to modulate Rho mediated signaling pathways may lend themselves as targets for small molecule therapeutic agents against cancer.
Keywords: Rho, RhoGAP, signal transduction, GTPase activating proteins, transformation, invasion, metastasis, cytoskeleton, interacting proteins, drug targets
Current Protein & Peptide Science
Title: Rho GTPase Activating Proteins in Cancer Phenotypes
Volume: 7 Issue: 4
Author(s): Raj P. Kandpal
Affiliation:
Keywords: Rho, RhoGAP, signal transduction, GTPase activating proteins, transformation, invasion, metastasis, cytoskeleton, interacting proteins, drug targets
Abstract: Rho proteins belong to the Ras superfamily of small GTPases and function as binary switches that shuttle between active and inactive states based on the nature of bound guanine nucleotide. Three sets of regulatory proteins, namely, guanine dissociation inhibitors, guanine exchange factors, and GTPase activating proteins (GAPs) control the balance between active and inactive Rho proteins. There are more than 70 RhoGAPs encoded in the human genome. The RhoGAP family is distinguished by the presence of the RhoGAP domain. However, the majority of RhoGAPs contain multiple additional domains. There are as many as eight domains in some of these proteins. The modular structure of GAPs is important for their interaction with other proteins. A significant number of RhoGAPs have been shown to be present in altered abundance in a variety of human cancers or cell lines. The ability of RhoGAPs to modulate Rho mediated signaling pathways may lend themselves as targets for small molecule therapeutic agents against cancer.
Export Options
About this article
Cite this article as:
P. Kandpal Raj, Rho GTPase Activating Proteins in Cancer Phenotypes, Current Protein & Peptide Science 2006; 7 (4) . https://dx.doi.org/10.2174/138920306778018025
DOI https://dx.doi.org/10.2174/138920306778018025 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Multifarious Medical Applications of Carbon Curvatures: A Cohort review
Current Bioactive Compounds CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Current Approaches for Drug Delivery to Central Nervous System
Current Drug Delivery Progress on Multi-Modality Molecular Imaging
Current Medical Imaging Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Nerve Growth Factor: Early Studies and Recent Clinical Trials
Current Neuropharmacology Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Schiff Bases and Complexes: A Review on Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Stem Cell and Regenerative Medicine
Current Stem Cell Research & Therapy HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Applications of Muscle Electroporation Gene Therapy
Current Gene Therapy Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry